Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV vaccine rationale, design and testing.

Karen S Slobod1, Chris Coleclough, Mattia Bonsignori

  • 1Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA.

Current HIV Research
|April 28, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sub-neutralizing concentrations of Zika virus IgM monoclonal antibodies reduce IgG-mediated antibody-dependent enhancement of infectivity.

bioRxiv : the preprint server for biology·2026
Same author

Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.

The Journal of experimental medicine·2025
Same author

Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques.

Communications medicine·2025
Same author

Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1.

Vaccines·2025
Same author

Randomized Controlled Clinical Trial of Pediatric Pneumococcus and Hepatitis A Vaccinations With or Without a High-Dose Oral Vitamin A Supplement.

Biomolecules·2025
Same author

Proceedings of the second annual dengue endgame summit: A call to action.

PLoS neglected tropical diseases·2025

Designing a global HIV vaccine faces challenges due to viral diversity. A successful HIV vaccine likely requires a cocktail approach, similar to existing vaccines, to address diverse envelope proteins and stimulate immune responses.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Viral diversity, specifically in envelope proteins, presents a significant obstacle to developing a global HIV vaccine.
  • Distinct HIV serotypes exist, where antibodies against one serotype's envelope proteins do not bind to others, complicating vaccine design.

Purpose of the Study:

  • To review data relevant to the development of cocktail vaccines for HIV.
  • To explore strategies for harnessing diverse, envelope-specific B-cell and T-cell responses.

Main Methods:

  • Review of existing data on HIV viral diversity and vaccine design strategies.
  • Analysis of successful cocktail vaccine approaches for other pathogens (e.g., poliovirus, pneumococcus).

Main Results:

Related Experiment Videos

  • Antigenic diversity of HIV envelope proteins is a key challenge for vaccine development.
  • Existing vaccines for pathogens with antigenic diversity utilize a cocktail approach.

Conclusions:

  • A successful HIV vaccine will likely need to comprise a cocktail of antigens to overcome viral diversity.
  • Cocktail vaccines can be designed to elicit diverse B-cell and T-cell responses against HIV envelope proteins.